Study of bioequivalence of a drug from the group of oral anticoagulants

17 August 2020

CFD begins preparing the final report on the results of a clinical study of the bioequivalence of a drug from the group of oral anticoagulants.

Back to the list

The first bioanalogue of the original drug for the treatment of osteoporosis in Russia has received a registration certificate from the Ministry of Health.

A phase I study of an innovative drug used in the treatment of patients with a new coronavirus infection (COVID-19) has been completed. The final report has been prepared.

Subscribe to the newsletter of interesting articles and news

Study of bioe­quiv­a­lence of a drug from the group of oral anti­co­ag­u­lants

Study of bioequivalence of a drug from the group of oral anticoagulants